RECRUITINGOBSERVATIONAL
Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study
Enquête épidémiologique Sur la prévalence et le Pronostic de l'Histiocytose Langerhansienne Pulmonaire de l'Adulte en France
About This Trial
The long-term outcomes of adult patients with pulmonary Langerhans cell histiocytosis (PLCH), particularly survival, is largely unknown. This is the first prospective study in the field evaluating the long-term outcomes of PLCH patients. This french countrywide registry-based study included a large cohort of PLCH patients followed for a sufficiently long period to address risk factors of long-term outcomes of PLCH patients.
Who May Be Eligible (Plain English)
Who May Qualify:
- Age \>= 18 years
- Diagnosis of PLCH was either diagnosed by tissue sample (biopsy-confirmed) on a biopsy of an involved tissue, or based on the combination of the following criteria: 1) an appropriate clinical picture; 2) a typical nodulo-cystic pattern on lung high-resolution computed tomography (HRCT) and 3) exclusion of alternative diagnoses
Who Should NOT Join This Trial:
\-
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Age \>= 18 years
* Diagnosis of PLCH was either histologically confirmed on a biopsy of an involved tissue, or based on the combination of the following criteria: 1) an appropriate clinical picture; 2) a typical nodulo-cystic pattern on lung high-resolution computed tomography (HRCT) and 3) exclusion of alternative diagnoses
Exclusion Criteria:
\-
Treatments Being Tested
OTHER
Standard of care
Standard of car of pulmonary Langerhans cell histiocytosis (PLCH)
Locations (1)
French national reference centre for Histiocytoses
Paris, France